Abstract
A method for manipulating whole antibodies to create preferentially-associating heterodimers is described. This technique relies on the simple idea of introducing bulky residues at the CH3 dimer interface, disrupting homodimer assembly. Cavities created in opposing positions in another CH3 domain, permits the assembly of a ‘knob-into-hole’ heterodimer, resulting in a heterodimer yield of over 95%, compared to a possible mixture of ten products by conventional approaches. Heterodimers such as these result in bispecific antibodies (BsAbs) that have wide utility in target-effector cell targeting and tumour cell-specific delivery of therapeutic agents.